hrcak mascot   Srce   HID

Izvorni znanstveni članak

Association of Cyp2c9 Gene Polymorphism with Bleeding as a Complication of Warfarin Therapy

Elizabeta Topić
Mario Štefanović
Lada Zibar
Goran Samardžija
Sanja Balen
Aleksandar Včev
Dragoslav Domanović
Jure Mirat
Jerko Barbić

Puni tekst: engleski, pdf (85 KB) str. 557-564 preuzimanja: 292* citiraj
APA 6th Edition
Topić, E., Štefanović, M., Zibar, L., Samardžija, G., Balen, S., Včev, A., ... Barbić, J. (2008). Association of Cyp2c9 Gene Polymorphism with Bleeding as a Complication of Warfarin Therapy. Collegium antropologicum, 32 (2), 557-564. Preuzeto s https://hrcak.srce.hr/27204
MLA 8th Edition
Topić, Elizabeta, et al. "Association of Cyp2c9 Gene Polymorphism with Bleeding as a Complication of Warfarin Therapy." Collegium antropologicum, vol. 32, br. 2, 2008, str. 557-564. https://hrcak.srce.hr/27204. Citirano 20.11.2019.
Chicago 17th Edition
Topić, Elizabeta, Mario Štefanović, Lada Zibar, Goran Samardžija, Sanja Balen, Aleksandar Včev, Dragoslav Domanović, Jure Mirat i Jerko Barbić. "Association of Cyp2c9 Gene Polymorphism with Bleeding as a Complication of Warfarin Therapy." Collegium antropologicum 32, br. 2 (2008): 557-564. https://hrcak.srce.hr/27204
Harvard
Topić, E., et al. (2008). 'Association of Cyp2c9 Gene Polymorphism with Bleeding as a Complication of Warfarin Therapy', Collegium antropologicum, 32(2), str. 557-564. Preuzeto s: https://hrcak.srce.hr/27204 (Datum pristupa: 20.11.2019.)
Vancouver
Topić E, Štefanović M, Zibar L, Samardžija G, Balen S, Včev A i sur. Association of Cyp2c9 Gene Polymorphism with Bleeding as a Complication of Warfarin Therapy. Collegium antropologicum [Internet]. 2008 [pristupljeno 20.11.2019.];32(2):557-564. Dostupno na: https://hrcak.srce.hr/27204
IEEE
E. Topić, et al., "Association of Cyp2c9 Gene Polymorphism with Bleeding as a Complication of Warfarin Therapy", Collegium antropologicum, vol.32, br. 2, str. 557-564, 2008. [Online]. Dostupno na: https://hrcak.srce.hr/27204. [Citirano: 20.11.2019.]

Sažetak
The aim of this study was to determine the association of bleeding as a complication of warfarin therapy with polymorphism
of CYP2C9 gene (alleles 1, 2 and 3). The CYP2C9 is the main enzyme for warfarin metabolism. Study included
181 patients receiving warfarin for at least one month. Allele 1 of CYP2C9 gene (in 94.5%) and genotype *1/*1
(57.5%) prevailed. Allele 3 was found in 12.7% patients. Bleeding side-effects occurred in 18 patients (10%). Patients
with allele *1 needed significantly higher maintenance warfarin dose (p=0.011). Those with allele *3 had significantly
lower maintenance warfarin dose (p=0.005) and higher prothrombin time (PT) at induction (p=0.034). Bleeding occurred
significantly more often in those with lower maintenance warfarin dose (p=0.017). Patients with allele *3 had increased
risk of bleeding, with marginal significance (p=0.05). Polymorphism of CYP2C9 could determine dose of warfarin
therapy and thus it could be related to the risk of bleeding complications. Allele *3 carriers need lower warfarin dose.
Therefore, initially reduced warfarin induction dose in allele *3 carriers could avoid more prolonged PT and decrease
the risk of bleeding complication.

Ključne riječi
gene polymorphism; CYP2C9; warfarin; bleeding

Hrčak ID: 27204

URI
https://hrcak.srce.hr/27204

Posjeta: 499 *